upadacitinib vs ZL-82

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atopic Dermatitis

Shared mechanism: JAK · full Atopic Dermatitis pipeline

upadacitinib · Rinvoq

Marketed by AbbVie

Approved in Atopic DermatitisSmall molecule (JAK1-selective inhibitor)
Reliable signal

NCT03607422 · Phase 3 · completed

Participants were randomized and the trial was quadruple-blinded and placebo-controlled in 912 adolescents and adults. Both co-primary endpoints -- a 75% reduction in the validated Eczema Area and Severity Index (EASI75) and clearance or near-clearance on the validated Investigator Global Assessment -- were clearly met for both upadacitinib doses versus placebo at week 16 (p<0.001 for all comparisons).

Next expected readout: November 2026 · NCT06389136 (registry estimate)

Reported efficacy

Main Study: Percentage of Participants Achieving at Least a 75% Reduction in Eczema Area and Severity Index Score (EASI 75) From Baseline at Week 16 (Baseline and Week 16); Main Study: Percentage of Participants Achieving Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) of 0 or 1 With a Reduction From Baseline of ≥ 2 Points at Week 16 (Baseline and Week 16): EASI-75 response at week 16 (Measure Up 2): 60.1% (upadacitinib 15 mg) vs 72.9% (upadacitinib 30 mg) vs 13.3% (placebo). (met)

Result source: NCT03607422

ZL-82

Developed by Chengdu Zenitar Biomedical Technology

Phase 2 in Atopic DermatitisSmall molecule (oral JAK3 inhibitor)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2027 · NCT07193589 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Atopic Dermatitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointupadacitinibZL-82
EASI-7560.1% vs 13.3%+46.8 vs placebo15 mg QD · wk 16 · n 276NCT03607422
63 other results
  • 69.6% vs 16.3% 15 mg QD · wk 16 · n 281 · Phase 3 · primary NCT03569293
  • 72.9% vs 13.3% 30 mg QD · wk 16 · n 282 · Phase 3 · primary NCT03607422
  • 79.7% vs 16.3% 30 mg QD · wk 16 · n 285 · Phase 3 · primary NCT03569293
  • 72.4% vs 62.6% 30 mg QD · wk 16 · n 342 · Phase 3 · primary NCT03738397
  • 33% vs 3.6% 15 mg QD · wk 2 · n 276 · Phase 3 · secondary NCT03607422
  • 38.1% vs 3.6% 15 mg QD · wk 2 · n 281 · Phase 3 · secondary NCT03569293
  • 44% vs 3.6% 30 mg QD · wk 2 · n 282 · Phase 3 · secondary NCT03607422
  • 47.4% vs 3.6% 30 mg QD · wk 2 · n 285 · Phase 3 · secondary NCT03569293
  • 69% vs 13.3% 15 mg QD · wk 16 · n 58 · Phase 3 · secondary NCT03607422
  • 74.6% vs 12.1% 15 mg QD · wk 16 · n 63 · Phase 3 · secondary NCT03569293
  • 37.9% vs 6.7% 15 mg QD · wk 2 · n 58 · Phase 3 · secondary NCT03607422
  • 39.7% vs 3.4% 15 mg QD · wk 2 · n 63 · Phase 3 · secondary NCT03569293
  • 73.4% vs 13.3% 30 mg QD · wk 16 · n 62 · Phase 3 · secondary NCT03607422
  • 84.5% vs 12.1% 30 mg QD · wk 16 · n 58 · Phase 3 · secondary NCT03569293
  • 53.2% vs 6.7% 30 mg QD · wk 2 · n 62 · Phase 3 · secondary NCT03607422
  • 55.8% vs 3.4% 30 mg QD · wk 2 · n 58 · Phase 3 · secondary NCT03569293
  • 44.3% vs 18.2% 30 mg QD · wk 2 · n 342 · Phase 3 · secondary NCT03738397
  • 52.4% vs 9.8% 15 mg · wk 16 · n 42 · Phase 2 · secondary NCT02925117
  • 52.4% vs 7.3% 15 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
  • 69% vs 9.8% 30 mg · wk 16 · n 42 · Phase 2 · secondary NCT02925117
  • 81% vs 7.3% 30 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
  • 28.6% vs 9.8% 7.5 mg · wk 16 · n 42 · Phase 2 · secondary NCT02925117
  • 31% vs 7.3% 7.5 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 15 mg · wk 88 · n 7 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 15 mg · wk 88 · n 8 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 15 mg · wk 76 · n 7 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 15 mg · wk 76 · n 8 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 15 mg · wk 64 · n 7 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 15 mg · wk 64 · n 8 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 15 mg · wk 52 · n 7 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 15 mg · wk 52 · n 8 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 15 mg · wk 40 · n 7 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 15 mg · wk 40 · n 8 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 15 mg · wk 32 · n 7 · Phase 2 · secondary NCT02925117
  • 50% vs 100% 15 mg · wk 32 · n 8 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 15 mg · wk 24 · n 7 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 15 mg · wk 24 · n 8 · Phase 2 · secondary NCT02925117
  • 0% vs 11.1% 15 mg · wk 20 · n 7 · Phase 2 · secondary NCT02925117
  • 12.5% vs 11.1% 15 mg · wk 20 · n 8 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 30 mg · wk 88 · n 8 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 30 mg · wk 88 · n 4 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 30 mg · wk 76 · n 8 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 30 mg · wk 76 · n 4 · Phase 2 · secondary NCT02925117
  • 80% vs 100% 30 mg · wk 64 · n 8 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 30 mg · wk 64 · n 4 · Phase 2 · secondary NCT02925117
  • 66.7% vs 100% 30 mg · wk 52 · n 8 · Phase 2 · secondary NCT02925117
  • 50% vs 100% 30 mg · wk 52 · n 4 · Phase 2 · secondary NCT02925117
  • 66.7% vs 100% 30 mg · wk 40 · n 8 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 30 mg · wk 40 · n 5 · Phase 2 · secondary NCT02925117
  • 50% vs 100% 30 mg · wk 40 · n 4 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 30 mg · wk 32 · n 8 · Phase 2 · secondary NCT02925117
  • 50% vs 100% 30 mg · wk 32 · n 5 · Phase 2 · secondary NCT02925117
  • 50% vs 100% 30 mg · wk 32 · n 4 · Phase 2 · secondary NCT02925117
  • 85.7% vs 100% 30 mg · wk 24 · n 8 · Phase 2 · secondary NCT02925117
  • 33.3% vs 100% 30 mg · wk 24 · n 5 · Phase 2 · secondary NCT02925117
  • 33.3% vs 100% 30 mg · wk 24 · n 4 · Phase 2 · secondary NCT02925117
  • 12.5% vs 11.1% 30 mg · wk 20 · n 8 · Phase 2 · secondary NCT02925117
  • 20% vs 11.1% 30 mg · wk 20 · n 5 · Phase 2 · secondary NCT02925117
  • 25% vs 11.1% 30 mg · wk 20 · n 4 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 7.5 mg · wk 32 · n 11 · Phase 2 · secondary NCT02925117
  • 33.3% vs 100% 7.5 mg · wk 24 · n 11 · Phase 2 · secondary NCT02925117
  • 0% vs 11.1% 7.5 mg · wk 20 · n 10 · Phase 2 · secondary NCT02925117
  • 9.1% vs 11.1% 7.5 mg · wk 20 · n 11 · Phase 2 · secondary NCT02925117
—Not reported
IGA 0/1 with 2-point improvement—Trial running · NCT03568318—Not reported
EASI-9042.4% vs 5.4%+37 vs placebo15 mg QD · wk 16 · n 276NCT03607422
14 other results
  • 53.1% vs 8.1% 15 mg QD · wk 16 · n 281 · Phase 3 · secondary NCT03569293
  • 58.5% vs 5.4% 30 mg QD · wk 16 · n 282 · Phase 3 · secondary NCT03607422
  • 65.8% vs 8.1% 30 mg QD · wk 16 · n 285 · Phase 3 · secondary NCT03569293
  • 48.3% vs 1.7% 15 mg QD · wk 16 · n 58 · Phase 3 · secondary NCT03607422
  • 47.6% vs 3.4% 15 mg QD · wk 16 · n 63 · Phase 3 · secondary NCT03569293
  • 62% vs 1.7% 30 mg QD · wk 16 · n 62 · Phase 3 · secondary NCT03607422
  • 74.1% vs 3.4% 30 mg QD · wk 16 · n 58 · Phase 3 · secondary NCT03569293
  • 61.6% vs 40.3% 30 mg QD · wk 16 · n 342 · Phase 3 · secondary NCT03738397
  • 26.2% vs 2.4% 15 mg · wk 16 · n 42 · Phase 2 · secondary NCT02925117
  • 26.2% vs 0% 15 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
  • 50% vs 2.4% 30 mg · wk 16 · n 42 · Phase 2 · secondary NCT02925117
  • 45.2% vs 0% 30 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
  • 14.3% vs 2.4% 7.5 mg · wk 16 · n 42 · Phase 2 · secondary NCT02925117
  • 9.5% vs 0% 7.5 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
—Not reported
EASI, % change-74.1% vs -34.5%−39.6 vs placebo15 mg QD · wk 16 · n 246NCT03607422
69 other results
  • -80.2% vs -40.7% 15 mg QD · wk 16 · n 244 · Phase 3 · secondary NCT03569293
  • -84.7% vs -34.5% 30 mg QD · wk 16 · n 250 · Phase 3 · secondary NCT03607422
  • -87.7% vs -40.7% 30 mg QD · wk 16 · n 259 · Phase 3 · secondary NCT03569293
  • -77.8% vs -42.2% 15 mg QD · wk 16 · n 53 · Phase 3 · secondary NCT03607422
  • -82.1% vs -43.5% 15 mg QD · wk 16 · n 59 · Phase 3 · secondary NCT03569293
  • -84.8% vs -42.2% 30 mg QD · wk 16 · n 52 · Phase 3 · secondary NCT03607422
  • -89.4% vs -43.5% 30 mg QD · wk 16 · n 57 · Phase 3 · secondary NCT03569293
  • -61.7% vs -23% 15 mg · wk 16 · n 42 · Phase 2 · primary NCT02925117
  • -74.4% vs -23% 30 mg · wk 16 · n 42 · Phase 2 · primary NCT02925117
  • -39.4% vs -23% 7.5 mg · wk 16 · n 42 · Phase 2 · primary NCT02925117
  • 617.5% vs -37.7% 15 mg · wk 88 · n 17 · Phase 2 · secondary NCT02925117
  • 99.3% vs -37.7% 15 mg · wk 88 · n 18 · Phase 2 · secondary NCT02925117
  • 614% vs -37.3% 15 mg · wk 76 · n 17 · Phase 2 · secondary NCT02925117
  • 130.2% vs -37.3% 15 mg · wk 76 · n 18 · Phase 2 · secondary NCT02925117
  • 614.6% vs -35.8% 15 mg · wk 64 · n 17 · Phase 2 · secondary NCT02925117
  • 104.1% vs -35.8% 15 mg · wk 64 · n 18 · Phase 2 · secondary NCT02925117
  • 613.8% vs -29.8% 15 mg · wk 52 · n 17 · Phase 2 · secondary NCT02925117
  • 104.1% vs -29.8% 15 mg · wk 52 · n 18 · Phase 2 · secondary NCT02925117
  • 608.8% vs -31.2% 15 mg · wk 40 · n 17 · Phase 2 · secondary NCT02925117
  • 154.1% vs -31.2% 15 mg · wk 40 · n 18 · Phase 2 · secondary NCT02925117
  • 613.3% vs -2.3% 15 mg · wk 32 · n 17 · Phase 2 · secondary NCT02925117
  • 151.7% vs -2.3% 15 mg · wk 32 · n 18 · Phase 2 · secondary NCT02925117
  • 607.3% vs 13.5% 15 mg · wk 24 · n 17 · Phase 2 · secondary NCT02925117
  • 72.6% vs 13.5% 15 mg · wk 24 · n 18 · Phase 2 · secondary NCT02925117
  • 582.3% vs 50.7% 15 mg · wk 20 · n 17 · Phase 2 · secondary NCT02925117
  • 65.7% vs 50.7% 15 mg · wk 20 · n 18 · Phase 2 · secondary NCT02925117
  • -65.4% vs -17.5% 15 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
  • -84.6% vs -37.7% 30 mg · wk 88 · n 10 · Phase 2 · secondary NCT02925117
  • 769.7% vs -37.7% 30 mg · wk 88 · n 14 · Phase 2 · secondary NCT02925117
  • 39% vs -37.7% 30 mg · wk 88 · n 19 · Phase 2 · secondary NCT02925117
  • -90.3% vs -37.3% 30 mg · wk 76 · n 10 · Phase 2 · secondary NCT02925117
  • 787.8% vs -37.3% 30 mg · wk 76 · n 14 · Phase 2 · secondary NCT02925117
  • 24.4% vs -37.3% 30 mg · wk 76 · n 19 · Phase 2 · secondary NCT02925117
  • -91.4% vs -35.8% 30 mg · wk 64 · n 10 · Phase 2 · secondary NCT02925117
  • 802.1% vs -35.8% 30 mg · wk 64 · n 14 · Phase 2 · secondary NCT02925117
  • 63.6% vs -35.8% 30 mg · wk 64 · n 19 · Phase 2 · secondary NCT02925117
  • -90.1% vs -29.8% 30 mg · wk 52 · n 10 · Phase 2 · secondary NCT02925117
  • 799.5% vs -29.8% 30 mg · wk 52 · n 14 · Phase 2 · secondary NCT02925117
  • -13.3% vs -29.8% 30 mg · wk 52 · n 19 · Phase 2 · secondary NCT02925117
  • -92% vs -31.2% 30 mg · wk 40 · n 10 · Phase 2 · secondary NCT02925117
  • 778.9% vs -31.2% 30 mg · wk 40 · n 14 · Phase 2 · secondary NCT02925117
  • 140.6% vs -31.2% 30 mg · wk 40 · n 19 · Phase 2 · secondary NCT02925117
  • -69.6% vs 13.5% 30 mg · wk 24 · n 19 · Phase 2 · secondary NCT02925117
  • -73.8% vs 50.7% 30 mg · wk 20 · n 19 · Phase 2 · secondary NCT02925117
  • -82.8% vs -17.5% 30 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
  • -83.1% vs -2.3% 30 mg · wk 32 · n 10 · Phase 2 · secondary NCT02925117
  • 771.5% vs -2.3% 30 mg · wk 32 · n 14 · Phase 2 · secondary NCT02925117
  • -28.8% vs -2.3% 30 mg · wk 32 · n 19 · Phase 2 · secondary NCT02925117
  • -67.5% vs 13.5% 30 mg · wk 24 · n 10 · Phase 2 · secondary NCT02925117
  • 898.5% vs 13.5% 30 mg · wk 24 · n 14 · Phase 2 · secondary NCT02925117
  • 181.5% vs -2.3% 7.5 mg · wk 32 · n 15 · Phase 2 · secondary NCT02925117
  • 63.5% vs -2.3% 7.5 mg · wk 32 · n 15 · Phase 2 · secondary NCT02925117
  • 189.6% vs 13.5% 7.5 mg · wk 24 · n 15 · Phase 2 · secondary NCT02925117
  • 59% vs 13.5% 7.5 mg · wk 24 · n 15 · Phase 2 · secondary NCT02925117
  • 186% vs 50.7% 7.5 mg · wk 20 · n 15 · Phase 2 · secondary NCT02925117
  • 79.1% vs 50.7% 7.5 mg · wk 20 · n 15 · Phase 2 · secondary NCT02925117
  • -43.7% vs -17.5% 7.5 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
  • 11.8% vs 50.7% 30 mg · wk 20 · n 10 · Phase 2 · secondary NCT02925117
  • 791.5% vs 50.7% 30 mg · wk 20 · n 14 · Phase 2 · secondary NCT02925117
  • 170.7% vs -37.7% 7.5 mg · wk 88 · n 15 · Phase 2 · secondary NCT02925117
  • 69.1% vs -37.7% 7.5 mg · wk 88 · n 15 · Phase 2 · secondary NCT02925117
  • 201.4% vs -37.3% 7.5 mg · wk 76 · n 15 · Phase 2 · secondary NCT02925117
  • 77.7% vs -37.3% 7.5 mg · wk 76 · n 15 · Phase 2 · secondary NCT02925117
  • 179.9% vs -35.8% 7.5 mg · wk 64 · n 15 · Phase 2 · secondary NCT02925117
  • 71.8% vs -35.8% 7.5 mg · wk 64 · n 15 · Phase 2 · secondary NCT02925117
  • 189.1% vs -29.8% 7.5 mg · wk 52 · n 15 · Phase 2 · secondary NCT02925117
  • 74.4% vs -29.8% 7.5 mg · wk 52 · n 15 · Phase 2 · secondary NCT02925117
  • 200.9% vs -31.2% 7.5 mg · wk 40 · n 15 · Phase 2 · secondary NCT02925117
  • 77.6% vs -31.2% 7.5 mg · wk 40 · n 15 · Phase 2 · secondary NCT02925117
—Not reported

EASI-75

upadacitinib
60.1% vs 13.3%+46.8 vs placebo15 mg QD · wk 16 · n 276NCT03607422
63 other results
  • 69.6% vs 16.3% 15 mg QD · wk 16 · n 281 · Phase 3 · primary NCT03569293
  • 72.9% vs 13.3% 30 mg QD · wk 16 · n 282 · Phase 3 · primary NCT03607422
  • 79.7% vs 16.3% 30 mg QD · wk 16 · n 285 · Phase 3 · primary NCT03569293
  • 72.4% vs 62.6% 30 mg QD · wk 16 · n 342 · Phase 3 · primary NCT03738397
  • 33% vs 3.6% 15 mg QD · wk 2 · n 276 · Phase 3 · secondary NCT03607422
  • 38.1% vs 3.6% 15 mg QD · wk 2 · n 281 · Phase 3 · secondary NCT03569293
  • 44% vs 3.6% 30 mg QD · wk 2 · n 282 · Phase 3 · secondary NCT03607422
  • 47.4% vs 3.6% 30 mg QD · wk 2 · n 285 · Phase 3 · secondary NCT03569293
  • 69% vs 13.3% 15 mg QD · wk 16 · n 58 · Phase 3 · secondary NCT03607422
  • 74.6% vs 12.1% 15 mg QD · wk 16 · n 63 · Phase 3 · secondary NCT03569293
  • 37.9% vs 6.7% 15 mg QD · wk 2 · n 58 · Phase 3 · secondary NCT03607422
  • 39.7% vs 3.4% 15 mg QD · wk 2 · n 63 · Phase 3 · secondary NCT03569293
  • 73.4% vs 13.3% 30 mg QD · wk 16 · n 62 · Phase 3 · secondary NCT03607422
  • 84.5% vs 12.1% 30 mg QD · wk 16 · n 58 · Phase 3 · secondary NCT03569293
  • 53.2% vs 6.7% 30 mg QD · wk 2 · n 62 · Phase 3 · secondary NCT03607422
  • 55.8% vs 3.4% 30 mg QD · wk 2 · n 58 · Phase 3 · secondary NCT03569293
  • 44.3% vs 18.2% 30 mg QD · wk 2 · n 342 · Phase 3 · secondary NCT03738397
  • 52.4% vs 9.8% 15 mg · wk 16 · n 42 · Phase 2 · secondary NCT02925117
  • 52.4% vs 7.3% 15 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
  • 69% vs 9.8% 30 mg · wk 16 · n 42 · Phase 2 · secondary NCT02925117
  • 81% vs 7.3% 30 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
  • 28.6% vs 9.8% 7.5 mg · wk 16 · n 42 · Phase 2 · secondary NCT02925117
  • 31% vs 7.3% 7.5 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 15 mg · wk 88 · n 7 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 15 mg · wk 88 · n 8 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 15 mg · wk 76 · n 7 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 15 mg · wk 76 · n 8 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 15 mg · wk 64 · n 7 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 15 mg · wk 64 · n 8 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 15 mg · wk 52 · n 7 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 15 mg · wk 52 · n 8 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 15 mg · wk 40 · n 7 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 15 mg · wk 40 · n 8 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 15 mg · wk 32 · n 7 · Phase 2 · secondary NCT02925117
  • 50% vs 100% 15 mg · wk 32 · n 8 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 15 mg · wk 24 · n 7 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 15 mg · wk 24 · n 8 · Phase 2 · secondary NCT02925117
  • 0% vs 11.1% 15 mg · wk 20 · n 7 · Phase 2 · secondary NCT02925117
  • 12.5% vs 11.1% 15 mg · wk 20 · n 8 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 30 mg · wk 88 · n 8 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 30 mg · wk 88 · n 4 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 30 mg · wk 76 · n 8 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 30 mg · wk 76 · n 4 · Phase 2 · secondary NCT02925117
  • 80% vs 100% 30 mg · wk 64 · n 8 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 30 mg · wk 64 · n 4 · Phase 2 · secondary NCT02925117
  • 66.7% vs 100% 30 mg · wk 52 · n 8 · Phase 2 · secondary NCT02925117
  • 50% vs 100% 30 mg · wk 52 · n 4 · Phase 2 · secondary NCT02925117
  • 66.7% vs 100% 30 mg · wk 40 · n 8 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 30 mg · wk 40 · n 5 · Phase 2 · secondary NCT02925117
  • 50% vs 100% 30 mg · wk 40 · n 4 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 30 mg · wk 32 · n 8 · Phase 2 · secondary NCT02925117
  • 50% vs 100% 30 mg · wk 32 · n 5 · Phase 2 · secondary NCT02925117
  • 50% vs 100% 30 mg · wk 32 · n 4 · Phase 2 · secondary NCT02925117
  • 85.7% vs 100% 30 mg · wk 24 · n 8 · Phase 2 · secondary NCT02925117
  • 33.3% vs 100% 30 mg · wk 24 · n 5 · Phase 2 · secondary NCT02925117
  • 33.3% vs 100% 30 mg · wk 24 · n 4 · Phase 2 · secondary NCT02925117
  • 12.5% vs 11.1% 30 mg · wk 20 · n 8 · Phase 2 · secondary NCT02925117
  • 20% vs 11.1% 30 mg · wk 20 · n 5 · Phase 2 · secondary NCT02925117
  • 25% vs 11.1% 30 mg · wk 20 · n 4 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 7.5 mg · wk 32 · n 11 · Phase 2 · secondary NCT02925117
  • 33.3% vs 100% 7.5 mg · wk 24 · n 11 · Phase 2 · secondary NCT02925117
  • 0% vs 11.1% 7.5 mg · wk 20 · n 10 · Phase 2 · secondary NCT02925117
  • 9.1% vs 11.1% 7.5 mg · wk 20 · n 11 · Phase 2 · secondary NCT02925117
ZL-82
—Not reported

IGA 0/1 with 2-point improvement

upadacitinib
—Trial running · NCT03568318
ZL-82
—Not reported

EASI-90

upadacitinib
42.4% vs 5.4%+37 vs placebo15 mg QD · wk 16 · n 276NCT03607422
14 other results
  • 53.1% vs 8.1% 15 mg QD · wk 16 · n 281 · Phase 3 · secondary NCT03569293
  • 58.5% vs 5.4% 30 mg QD · wk 16 · n 282 · Phase 3 · secondary NCT03607422
  • 65.8% vs 8.1% 30 mg QD · wk 16 · n 285 · Phase 3 · secondary NCT03569293
  • 48.3% vs 1.7% 15 mg QD · wk 16 · n 58 · Phase 3 · secondary NCT03607422
  • 47.6% vs 3.4% 15 mg QD · wk 16 · n 63 · Phase 3 · secondary NCT03569293
  • 62% vs 1.7% 30 mg QD · wk 16 · n 62 · Phase 3 · secondary NCT03607422
  • 74.1% vs 3.4% 30 mg QD · wk 16 · n 58 · Phase 3 · secondary NCT03569293
  • 61.6% vs 40.3% 30 mg QD · wk 16 · n 342 · Phase 3 · secondary NCT03738397
  • 26.2% vs 2.4% 15 mg · wk 16 · n 42 · Phase 2 · secondary NCT02925117
  • 26.2% vs 0% 15 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
  • 50% vs 2.4% 30 mg · wk 16 · n 42 · Phase 2 · secondary NCT02925117
  • 45.2% vs 0% 30 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
  • 14.3% vs 2.4% 7.5 mg · wk 16 · n 42 · Phase 2 · secondary NCT02925117
  • 9.5% vs 0% 7.5 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
ZL-82
—Not reported

EASI, % change

upadacitinib
-74.1% vs -34.5%−39.6 vs placebo15 mg QD · wk 16 · n 246NCT03607422
69 other results
  • -80.2% vs -40.7% 15 mg QD · wk 16 · n 244 · Phase 3 · secondary NCT03569293
  • -84.7% vs -34.5% 30 mg QD · wk 16 · n 250 · Phase 3 · secondary NCT03607422
  • -87.7% vs -40.7% 30 mg QD · wk 16 · n 259 · Phase 3 · secondary NCT03569293
  • -77.8% vs -42.2% 15 mg QD · wk 16 · n 53 · Phase 3 · secondary NCT03607422
  • -82.1% vs -43.5% 15 mg QD · wk 16 · n 59 · Phase 3 · secondary NCT03569293
  • -84.8% vs -42.2% 30 mg QD · wk 16 · n 52 · Phase 3 · secondary NCT03607422
  • -89.4% vs -43.5% 30 mg QD · wk 16 · n 57 · Phase 3 · secondary NCT03569293
  • -61.7% vs -23% 15 mg · wk 16 · n 42 · Phase 2 · primary NCT02925117
  • -74.4% vs -23% 30 mg · wk 16 · n 42 · Phase 2 · primary NCT02925117
  • -39.4% vs -23% 7.5 mg · wk 16 · n 42 · Phase 2 · primary NCT02925117
  • 617.5% vs -37.7% 15 mg · wk 88 · n 17 · Phase 2 · secondary NCT02925117
  • 99.3% vs -37.7% 15 mg · wk 88 · n 18 · Phase 2 · secondary NCT02925117
  • 614% vs -37.3% 15 mg · wk 76 · n 17 · Phase 2 · secondary NCT02925117
  • 130.2% vs -37.3% 15 mg · wk 76 · n 18 · Phase 2 · secondary NCT02925117
  • 614.6% vs -35.8% 15 mg · wk 64 · n 17 · Phase 2 · secondary NCT02925117
  • 104.1% vs -35.8% 15 mg · wk 64 · n 18 · Phase 2 · secondary NCT02925117
  • 613.8% vs -29.8% 15 mg · wk 52 · n 17 · Phase 2 · secondary NCT02925117
  • 104.1% vs -29.8% 15 mg · wk 52 · n 18 · Phase 2 · secondary NCT02925117
  • 608.8% vs -31.2% 15 mg · wk 40 · n 17 · Phase 2 · secondary NCT02925117
  • 154.1% vs -31.2% 15 mg · wk 40 · n 18 · Phase 2 · secondary NCT02925117
  • 613.3% vs -2.3% 15 mg · wk 32 · n 17 · Phase 2 · secondary NCT02925117
  • 151.7% vs -2.3% 15 mg · wk 32 · n 18 · Phase 2 · secondary NCT02925117
  • 607.3% vs 13.5% 15 mg · wk 24 · n 17 · Phase 2 · secondary NCT02925117
  • 72.6% vs 13.5% 15 mg · wk 24 · n 18 · Phase 2 · secondary NCT02925117
  • 582.3% vs 50.7% 15 mg · wk 20 · n 17 · Phase 2 · secondary NCT02925117
  • 65.7% vs 50.7% 15 mg · wk 20 · n 18 · Phase 2 · secondary NCT02925117
  • -65.4% vs -17.5% 15 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
  • -84.6% vs -37.7% 30 mg · wk 88 · n 10 · Phase 2 · secondary NCT02925117
  • 769.7% vs -37.7% 30 mg · wk 88 · n 14 · Phase 2 · secondary NCT02925117
  • 39% vs -37.7% 30 mg · wk 88 · n 19 · Phase 2 · secondary NCT02925117
  • -90.3% vs -37.3% 30 mg · wk 76 · n 10 · Phase 2 · secondary NCT02925117
  • 787.8% vs -37.3% 30 mg · wk 76 · n 14 · Phase 2 · secondary NCT02925117
  • 24.4% vs -37.3% 30 mg · wk 76 · n 19 · Phase 2 · secondary NCT02925117
  • -91.4% vs -35.8% 30 mg · wk 64 · n 10 · Phase 2 · secondary NCT02925117
  • 802.1% vs -35.8% 30 mg · wk 64 · n 14 · Phase 2 · secondary NCT02925117
  • 63.6% vs -35.8% 30 mg · wk 64 · n 19 · Phase 2 · secondary NCT02925117
  • -90.1% vs -29.8% 30 mg · wk 52 · n 10 · Phase 2 · secondary NCT02925117
  • 799.5% vs -29.8% 30 mg · wk 52 · n 14 · Phase 2 · secondary NCT02925117
  • -13.3% vs -29.8% 30 mg · wk 52 · n 19 · Phase 2 · secondary NCT02925117
  • -92% vs -31.2% 30 mg · wk 40 · n 10 · Phase 2 · secondary NCT02925117
  • 778.9% vs -31.2% 30 mg · wk 40 · n 14 · Phase 2 · secondary NCT02925117
  • 140.6% vs -31.2% 30 mg · wk 40 · n 19 · Phase 2 · secondary NCT02925117
  • -69.6% vs 13.5% 30 mg · wk 24 · n 19 · Phase 2 · secondary NCT02925117
  • -73.8% vs 50.7% 30 mg · wk 20 · n 19 · Phase 2 · secondary NCT02925117
  • -82.8% vs -17.5% 30 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
  • -83.1% vs -2.3% 30 mg · wk 32 · n 10 · Phase 2 · secondary NCT02925117
  • 771.5% vs -2.3% 30 mg · wk 32 · n 14 · Phase 2 · secondary NCT02925117
  • -28.8% vs -2.3% 30 mg · wk 32 · n 19 · Phase 2 · secondary NCT02925117
  • -67.5% vs 13.5% 30 mg · wk 24 · n 10 · Phase 2 · secondary NCT02925117
  • 898.5% vs 13.5% 30 mg · wk 24 · n 14 · Phase 2 · secondary NCT02925117
  • 181.5% vs -2.3% 7.5 mg · wk 32 · n 15 · Phase 2 · secondary NCT02925117
  • 63.5% vs -2.3% 7.5 mg · wk 32 · n 15 · Phase 2 · secondary NCT02925117
  • 189.6% vs 13.5% 7.5 mg · wk 24 · n 15 · Phase 2 · secondary NCT02925117
  • 59% vs 13.5% 7.5 mg · wk 24 · n 15 · Phase 2 · secondary NCT02925117
  • 186% vs 50.7% 7.5 mg · wk 20 · n 15 · Phase 2 · secondary NCT02925117
  • 79.1% vs 50.7% 7.5 mg · wk 20 · n 15 · Phase 2 · secondary NCT02925117
  • -43.7% vs -17.5% 7.5 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
  • 11.8% vs 50.7% 30 mg · wk 20 · n 10 · Phase 2 · secondary NCT02925117
  • 791.5% vs 50.7% 30 mg · wk 20 · n 14 · Phase 2 · secondary NCT02925117
  • 170.7% vs -37.7% 7.5 mg · wk 88 · n 15 · Phase 2 · secondary NCT02925117
  • 69.1% vs -37.7% 7.5 mg · wk 88 · n 15 · Phase 2 · secondary NCT02925117
  • 201.4% vs -37.3% 7.5 mg · wk 76 · n 15 · Phase 2 · secondary NCT02925117
  • 77.7% vs -37.3% 7.5 mg · wk 76 · n 15 · Phase 2 · secondary NCT02925117
  • 179.9% vs -35.8% 7.5 mg · wk 64 · n 15 · Phase 2 · secondary NCT02925117
  • 71.8% vs -35.8% 7.5 mg · wk 64 · n 15 · Phase 2 · secondary NCT02925117
  • 189.1% vs -29.8% 7.5 mg · wk 52 · n 15 · Phase 2 · secondary NCT02925117
  • 74.4% vs -29.8% 7.5 mg · wk 52 · n 15 · Phase 2 · secondary NCT02925117
  • 200.9% vs -31.2% 7.5 mg · wk 40 · n 15 · Phase 2 · secondary NCT02925117
  • 77.6% vs -31.2% 7.5 mg · wk 40 · n 15 · Phase 2 · secondary NCT02925117
ZL-82
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

ZL-82: no structured comparison results are available for Atopic Dermatitis.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. upadacitinib: 4 of 4 rows · ZL-82: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricupadacitinib
Dropout rate
—15 mga
NCT03607422 · Phase 3
show 48 more results
—15 mg
NCT03607422 · Phase 3
5.2%15 mg QD
NCT03607422 · Phase 3
—15 mg
NCT03607422 · Phase 3
—15 mg
NCT03607422 · Phase 3
4.1%15 mg QD
NCT03607422 · Phase 3
—30 mg
NCT03607422 · Phase 3
—30 mg
NCT03607422 · Phase 3
3.2%30 mg QD
NCT03607422 · Phase 3
—30 mg
NCT03607422 · Phase 3
—30 mg
NCT03607422 · Phase 3
4.5%30 mg QD
NCT03607422 · Phase 3
—15 mg
NCT03569293 · Phase 3
—15 mg QD
NCT03569293 · Phase 3
0%15 mg QD
NCT03569293 · Phase 3
—15 mg
NCT03569293 · Phase 3
—15 mg
NCT03569293 · Phase 3
3.3%15 mg QD
NCT03569293 · Phase 3
—30 mg
NCT03569293 · Phase 3
—30 mg QD
NCT03569293 · Phase 3
0%30 mg QD
NCT03569293 · Phase 3
—30 mg
NCT03569293 · Phase 3
—30 mg
NCT03569293 · Phase 3
4.9%30 mg QD
NCT03569293 · Phase 3
5.2%15 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
—15 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
—15 mg then 30 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
2.6%30 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
—30 mg then 15 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
—30 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
10.5%30 mg
NCT04195698 · Phase 3 · registry result, not featured evidence
16.5%30 mg
NCT04195698 · Phase 3 · registry result, not featured evidence
8.8%30 mg QD
NCT03738397 · Phase 3 · registry result, not featured evidence
—15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
11.9%15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
7.1%30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
26.2%7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—15 mga
NCT03607422 · Phase 3
show 48 more results
—15 mg
NCT03607422 · Phase 3
3.4%15 mg QD
NCT03607422 · Phase 3
—15 mg
NCT03607422 · Phase 3
—15 mg
NCT03607422 · Phase 3
1.2%15 mg QD
NCT03607422 · Phase 3
—30 mg
NCT03607422 · Phase 3
—30 mg
NCT03607422 · Phase 3
0%30 mg QD
NCT03607422 · Phase 3
—30 mg
NCT03607422 · Phase 3
—30 mg
NCT03607422 · Phase 3
0.4%30 mg QD
NCT03607422 · Phase 3
—15 mg
NCT03569293 · Phase 3
—15 mg QD
NCT03569293 · Phase 3
0%15 mg QD
NCT03569293 · Phase 3
—15 mg
NCT03569293 · Phase 3
—15 mg
NCT03569293 · Phase 3
0.4%15 mg QD
NCT03569293 · Phase 3
—30 mg
NCT03569293 · Phase 3
—30 mg QD
NCT03569293 · Phase 3
0%30 mg QD
NCT03569293 · Phase 3
—30 mg
NCT03569293 · Phase 3
—30 mg
NCT03569293 · Phase 3
1.6%30 mg QD
NCT03569293 · Phase 3
—15 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
—15 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
—15 mg then 30 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
—30 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
—30 mg then 15 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
—30 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
1.7%30 mg
NCT04195698 · Phase 3 · registry result, not featured evidence
4.7%30 mg
NCT04195698 · Phase 3 · registry result, not featured evidence
2%30 mg QD
NCT03738397 · Phase 3 · registry result, not featured evidence
—15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
2.4%15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
4.8%30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
7.1%7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
Serious AEs
15.4%15 mga
NCT03607422 · Phase 3
show 48 more results
10.9%15 mg
NCT03607422 · Phase 3
3.4%15 mg QD
NCT03607422 · Phase 3
10.6%15 mg
NCT03607422 · Phase 3
16.6%15 mg
NCT03607422 · Phase 3
1.2%15 mg QD
NCT03607422 · Phase 3
13.8%30 mg
NCT03607422 · Phase 3
16.9%30 mg
NCT03607422 · Phase 3
0%30 mg QD
NCT03607422 · Phase 3
17.3%30 mg
NCT03607422 · Phase 3
17.4%30 mg
NCT03607422 · Phase 3
2.8%30 mg QD
NCT03607422 · Phase 3
3.3%15 mg
NCT03569293 · Phase 3
12.5%15 mg QD
NCT03569293 · Phase 3
3.1%15 mg QD
NCT03569293 · Phase 3
14.7%15 mg
NCT03569293 · Phase 3
14.3%15 mg
NCT03569293 · Phase 3
2.1%15 mg QD
NCT03569293 · Phase 3
22.2%30 mg
NCT03569293 · Phase 3
10.9%30 mg QD
NCT03569293 · Phase 3
0%30 mg QD
NCT03569293 · Phase 3
20%30 mg
NCT03569293 · Phase 3
18.4%30 mg
NCT03569293 · Phase 3
3.3%30 mg QD
NCT03569293 · Phase 3
3.5%15 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
1.4%15 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
0.7%15 mg then 30 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
0%30 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
0.8%30 mg then 15 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
0%30 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
5.9%30 mg
NCT04195698 · Phase 3 · registry result, not featured evidence
5.5%30 mg
NCT04195698 · Phase 3 · registry result, not featured evidence
4.1%30 mg QD
NCT03738397 · Phase 3 · registry result, not featured evidence
2.4%15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
2.4%15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
6.1%30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
0%30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
4.8%7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
4.8%7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
15 mga
covid-19 23.1% (placebo 0%)
acne 19.2% (placebo 3.3%)
dermatitis atopic 19.2% (placebo 13.3%)
NCT03607422 · Phase 3
show 38 more results
15 mg
covid-19 27.3% (placebo 0%)
upper respiratory tract infection 21.8% (placebo 1.7%)
acne 18.2% (placebo 3.3%)
NCT03607422 · Phase 3
15 mg QD
acne 10.3% (placebo 3.3%)
upper respiratory tract infection 10.3% (placebo 1.7%)
oropharyngeal pain 6.9% (placebo 0%)
NCT03607422 · Phase 3
15 mg
covid-19 31.7% (placebo 0%)
acne 19.2% (placebo 3.3%)
blood creatine phosphokinase increased 17.3% (placebo 1.7%)
NCT03607422 · Phase 3
15 mg
covid-19 31.9% (placebo 0%)
dermatitis atopic 17.9% (placebo 13.3%)
upper respiratory tract infection 14.4% (placebo 1.7%)
NCT03607422 · Phase 3
15 mg QD
acne 12.8% (placebo 3.3%)
headache 7% (placebo 3.3%)
nasopharyngitis 6.2% (placebo 3.3%)
NCT03607422 · Phase 3
30 mg
covid-19 41.4% (placebo 0%)
acne 34.5% (placebo 3.3%)
dermatitis atopic 24.1% (placebo 13.3%)
NCT03607422 · Phase 3
30 mg
covid-19 32.2% (placebo 0%)
blood creatine phosphokinase increased 18.6% (placebo 1.7%)
acne 11.9% (placebo 3.3%)
NCT03607422 · Phase 3
30 mg QD
acne 14.5% (placebo 3.3%)
blood creatine phosphokinase increased 9.7% (placebo 1.7%)
headache 8.1% (placebo 3.3%)
NCT03607422 · Phase 3
30 mg
covid-19 39.4% (placebo 0%)
acne 25% (placebo 3.3%)
dermatitis atopic 15.4% (placebo 13.3%)
NCT03607422 · Phase 3
30 mg
covid-19 29.8% (placebo 0%)
blood creatine phosphokinase increased 18.3% (placebo 1.7%)
dermatitis atopic 14.9% (placebo 13.3%)
NCT03607422 · Phase 3
30 mg QD
acne 15% (placebo 3.3%)
nasopharyngitis 8.1% (placebo 3.3%)
headache 6.5% (placebo 3.3%)
NCT03607422 · Phase 3
15 mg
covid-19 20% (placebo 0%)
acne 16.7% (placebo 1.6%)
blood creatine phosphokinase increased 16.7% (placebo 3.3%)
NCT03569293 · Phase 3
15 mg QD
covid-19 25% (placebo 0%)
upper respiratory tract infection 21.9% (placebo 8.2%)
blood creatine phosphokinase increased 12.5% (placebo 3.3%)
NCT03569293 · Phase 3
15 mg QD
acne 14.1% (placebo 1.6%)
blood creatine phosphokinase increased 7.8% (placebo 3.3%)
headache 7.8% (placebo 3.3%)
NCT03569293 · Phase 3
15 mg
covid-19 38.2% (placebo 0%)
dermatitis atopic 18.6% (placebo 3.3%)
upper respiratory tract infection 18.6% (placebo 8.2%)
NCT03569293 · Phase 3
15 mg
covid-19 28.6% (placebo 0%)
nasopharyngitis 16.5% (placebo 1.6%)
dermatitis atopic 16% (placebo 3.3%)
NCT03569293 · Phase 3
15 mg QD
upper respiratory tract infection 9.6% (placebo 8.2%)
nasopharyngitis 7.9% (placebo 1.6%)
acne 5.4% (placebo 1.6%)
NCT03569293 · Phase 3
30 mg
acne 37% (placebo 1.6%)
upper respiratory tract infection 33.3% (placebo 8.2%)
dermatitis atopic 29.6% (placebo 3.3%)
NCT03569293 · Phase 3
30 mg QD
covid-19 35.9% (placebo 0%)
acne 28.1% (placebo 1.6%)
upper respiratory tract infection 28.1% (placebo 8.2%)
NCT03569293 · Phase 3
30 mg QD
acne 15.6% (placebo 1.6%)
upper respiratory tract infection 12.5% (placebo 8.2%)
blood creatine phosphokinase increased 7.8% (placebo 3.3%)
NCT03569293 · Phase 3
30 mg
covid-19 38.1% (placebo 0%)
acne 22.9% (placebo 1.6%)
blood creatine phosphokinase increased 17.1% (placebo 3.3%)
NCT03569293 · Phase 3
30 mg
covid-19 35.1% (placebo 0%)
acne 18.9% (placebo 1.6%)
dermatitis atopic 18% (placebo 3.3%)
NCT03569293 · Phase 3
30 mg QD
acne 16.5% (placebo 1.6%)
upper respiratory tract infection 12.8% (placebo 8.2%)
nasopharyngitis 11.5% (placebo 1.6%)
NCT03569293 · Phase 3
15 mg
acne 7%
nasopharyngitis 5.7%
upper respiratory tract infection 3.5%
NCT05507580 · Phase 4 · registry result, not featured evidence
15 mg
nasopharyngitis 11.1%
dermatitis atopic 8.3%
upper respiratory tract infection 6.9%
NCT05507580 · Phase 4 · registry result, not featured evidence
15 mg then 30 mg
dermatitis atopic 16%
nasopharyngitis 4.2%
acne 2.8%
NCT05507580 · Phase 4 · registry result, not featured evidence
30 mg
acne 13.8%
nasopharyngitis 9.1%
dermatitis atopic 3.9%
NCT05507580 · Phase 4 · registry result, not featured evidence
30 mg then 15 mg
dermatitis atopic 12%
nasopharyngitis 7.5%
acne 6%
NCT05507580 · Phase 4 · registry result, not featured evidence
30 mg
dermatitis atopic 16.5%
acne 6.6%
eczema 5.5%
NCT05507580 · Phase 4 · registry result, not featured evidence
30 mg
acne 20.5%
covid-19 13.4%
blood creatine phosphokinase increased 13%
NCT04195698 · Phase 3 · registry result, not featured evidence
30 mg
acne 22.9%
dermatitis atopic 19.1%
blood creatine phosphokinase increased 14.8%
NCT04195698 · Phase 3 · registry result, not featured evidence
30 mg QD
acne 18.7%
dermatitis atopic 10.5%
blood creatine phosphokinase increased 7.6%
NCT03738397 · Phase 3 · registry result, not featured evidence
15 mg
upper respiratory tract infection 16.7% (placebo 5.4%)
dermatitis atopic 11.9% (placebo 2.2%)
nasopharyngitis 11.9% (placebo 1.1%)
NCT02925117 · Phase 2 · registry result, not featured evidence
15 mg
upper respiratory tract infection 11.9% (placebo 5.4%)
nasopharyngitis 9.5% (placebo 1.1%)
blood creatine phosphokinase increased 7.1% (placebo 3.2%)
NCT02925117 · Phase 2 · registry result, not featured evidence
30 mg
upper respiratory tract infection 22.8% (placebo 5.4%)
dermatitis atopic 19.3% (placebo 2.2%)
acne 11.4% (placebo 1.1%)
NCT02925117 · Phase 2 · registry result, not featured evidence
30 mg
acne 14.3% (placebo 1.1%)
upper respiratory tract infection 11.9% (placebo 5.4%)
blood creatine phosphokinase increased 9.5% (placebo 3.2%)
NCT02925117 · Phase 2 · registry result, not featured evidence
7.5 mg
upper respiratory tract infection 16.7% (placebo 5.4%)
dermatitis atopic 14.3% (placebo 2.2%)
acne 9.5% (placebo 1.1%)
NCT02925117 · Phase 2 · registry result, not featured evidence
7.5 mg
upper respiratory tract infection 16.7% (placebo 5.4%)
dermatitis atopic 11.9% (placebo 2.2%)
acne 9.5% (placebo 1.1%)
NCT02925117 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

upadacitinib

EASI-75 60.1% (n=276) vs 13.3% (n=278) placebo @ 16wk15 mg QD
responder rate · % of participants
NCT03607422 · Phase 3
show 63 more results
33% (n=276) vs 3.6% (n=278) placebo @ 2wk15 mg QD
NCT03607422 · Phase 3
69% (n=58) vs 13.3% (n=60) placebo @ 16wk15 mg QD
NCT03607422 · Phase 3
37.9% (n=58) vs 6.7% (n=60) placebo @ 2wk15 mg QD
NCT03607422 · Phase 3
69.6% (n=281) vs 16.3% (n=281) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
38.1% (n=281) vs 3.6% (n=281) placebo @ 2wk15 mg QD
NCT03569293 · Phase 3
74.6% (n=63) vs 12.1% (n=58) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
39.7% (n=63) vs 3.4% (n=58) placebo @ 2wk15 mg QD
NCT03569293 · Phase 3
52.4% (n=42) vs 9.8% (n=41) placebo @ 16wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
52.4% (n=42) vs 7.3% (n=41) placebo @ 8wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
0% (n=7) vs 11.1% (n=9) placebo @ 20wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
12.5% (n=8) vs 11.1% (n=9) placebo @ 20wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
0% (n=7) vs 100% (n=9) placebo @ 24wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
0% (n=8) vs 100% (n=9) placebo @ 24wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
0% (n=7) vs 100% (n=9) placebo @ 32wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
50% (n=8) vs 100% (n=9) placebo @ 32wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
0% (n=7) vs 100% (n=9) placebo @ 40wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
100% (n=8) vs 100% (n=9) placebo @ 40wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
0% (n=7) vs 100% (n=9) placebo @ 52wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
100% (n=8) vs 100% (n=9) placebo @ 52wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
0% (n=7) vs 100% (n=9) placebo @ 64wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
100% (n=8) vs 100% (n=9) placebo @ 64wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
0% (n=7) vs 100% (n=9) placebo @ 76wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
100% (n=8) vs 100% (n=9) placebo @ 76wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
0% (n=7) vs 100% (n=9) placebo @ 88wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
100% (n=8) vs 100% (n=9) placebo @ 88wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
72.9% (n=282) vs 13.3% (n=278) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
44% (n=282) vs 3.6% (n=278) placebo @ 2wk30 mg QD
NCT03607422 · Phase 3
73.4% (n=62) vs 13.3% (n=60) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
53.2% (n=62) vs 6.7% (n=60) placebo @ 2wk30 mg QD
NCT03607422 · Phase 3
79.7% (n=285) vs 16.3% (n=281) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
47.4% (n=285) vs 3.6% (n=281) placebo @ 2wk30 mg QD
NCT03569293 · Phase 3
84.5% (n=58) vs 12.1% (n=58) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
55.8% (n=58) vs 3.4% (n=58) placebo @ 2wk30 mg QD
NCT03569293 · Phase 3
72.4% (n=342) vs 62.6% (n=331) Dupilumab @ 16wk30 mg QD
NCT03738397 · Phase 3 · registry result, not featured evidence
44.3% (n=342) vs 18.2% (n=331) Dupilumab @ 2wk30 mg QD
NCT03738397 · Phase 3 · registry result, not featured evidence
69% (n=42) vs 9.8% (n=41) placebo @ 16wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
81% (n=42) vs 7.3% (n=41) placebo @ 8wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
12.5% (n=8) vs 11.1% (n=9) placebo @ 20wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
20% (n=5) vs 11.1% (n=9) placebo @ 20wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
25% (n=4) vs 11.1% (n=9) placebo @ 20wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
85.7% (n=8) vs 100% (n=9) placebo @ 24wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
33.3% (n=5) vs 100% (n=9) placebo @ 24wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
33.3% (n=4) vs 100% (n=9) placebo @ 24wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
100% (n=8) vs 100% (n=9) placebo @ 32wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
50% (n=5) vs 100% (n=9) placebo @ 32wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
50% (n=4) vs 100% (n=9) placebo @ 32wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
66.7% (n=8) vs 100% (n=9) placebo @ 40wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
0% (n=5) vs 100% (n=9) placebo @ 40wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
50% (n=4) vs 100% (n=9) placebo @ 40wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
66.7% (n=8) vs 100% (n=9) placebo @ 52wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
50% (n=4) vs 100% (n=9) placebo @ 52wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
80% (n=8) vs 100% (n=9) placebo @ 64wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
100% (n=4) vs 100% (n=9) placebo @ 64wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
100% (n=8) vs 100% (n=9) placebo @ 76wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
100% (n=4) vs 100% (n=9) placebo @ 76wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
100% (n=8) vs 100% (n=9) placebo @ 88wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
100% (n=4) vs 100% (n=9) placebo @ 88wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
28.6% (n=42) vs 9.8% (n=41) placebo @ 16wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
31% (n=42) vs 7.3% (n=41) placebo @ 8wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
0% (n=10) vs 11.1% (n=9) placebo @ 20wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
9.1% (n=11) vs 11.1% (n=9) placebo @ 20wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
33.3% (n=11) vs 100% (n=9) placebo @ 24wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
0% (n=11) vs 100% (n=9) placebo @ 32wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
vIGA-AD 0 1 38.8% (n=276) vs 4.7% (n=278) placebo @ 16wk15 mg QD
responder rate · % of participants
NCT03607422 · Phase 3
show 7 more results
44.8% (n=58) vs 5% (n=60) placebo @ 16wk15 mg QD
NCT03607422 · Phase 3
48.1% (n=281) vs 8.4% (n=281) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
46% (n=63) vs 6.9% (n=58) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
52% (n=282) vs 4.7% (n=278) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
59.4% (n=62) vs 5% (n=60) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
62% (n=285) vs 8.4% (n=281) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
70.7% (n=58) vs 6.9% (n=58) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
Worst Itch NRS 4-Point Improvement 41.9% (n=270) vs 9.1% (n=274) placebo @ 16wk15 mg QD
responder rate · % of participants
NCT03607422 · Phase 3
show 38 more results
48.9% (n=270) vs 3.6% (n=274) placebo @ 4wk15 mg QD
NCT03607422 · Phase 3
7.4% (n=270) vs 0.7% (n=274) placebo @ 1wk15 mg QD
NCT03607422 · Phase 3
7.4% (n=269) vs 0.7% (n=267) placebo @ 0.29wk15 mg QD
NCT03607422 · Phase 3
11.5% (n=269) vs 3% (n=267) placebo @ 0.43wk15 mg QD
NCT03607422 · Phase 3
38.2% (n=55) vs 3.4% (n=59) placebo @ 16wk15 mg QD
NCT03607422 · Phase 3
38.2% (n=55) vs 3.4% (n=59) placebo @ 4wk15 mg QD
NCT03607422 · Phase 3
12.7% (n=55) vs 0% (n=59) placebo @ 1wk15 mg QD
NCT03607422 · Phase 3
8.9% (n=56) vs 0% (n=59) placebo @ 0.29wk15 mg QD
NCT03607422 · Phase 3
14.3% (n=56) vs 1.7% (n=59) placebo @ 0.43wk15 mg QD
NCT03607422 · Phase 3
52.2% (n=274) vs 11.8% (n=272) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
51.5% (n=274) vs 4.4% (n=272) placebo @ 4wk15 mg QD
NCT03569293 · Phase 3
15% (n=274) vs 0.4% (n=272) placebo @ 1wk15 mg QD
NCT03569293 · Phase 3
10.5% (n=275) vs 3.7% (n=270) placebo @ 0.29wk15 mg QD
NCT03569293 · Phase 3
16.4% (n=275) vs 3.3% (n=270) placebo @ 0.43wk15 mg QD
NCT03569293 · Phase 3
49.2% (n=61) vs 10.5% (n=57) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
49.2% (n=61) vs 3.5% (n=57) placebo @ 4wk15 mg QD
NCT03569293 · Phase 3
9.8% (n=61) vs 0% (n=57) placebo @ 1wk15 mg QD
NCT03569293 · Phase 3
16.9% (n=59) vs 5.4% (n=56) placebo @ 0.43wk15 mg QD
NCT03569293 · Phase 3
59.6% (n=280) vs 9.1% (n=274) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
60.7% (n=280) vs 3.6% (n=274) placebo @ 4wk30 mg QD
NCT03607422 · Phase 3
15.7% (n=280) vs 0.7% (n=274) placebo @ 1wk30 mg QD
NCT03607422 · Phase 3
7.9% (n=278) vs 0.7% (n=267) placebo @ 0.29wk30 mg QD
NCT03607422 · Phase 3
17.3% (n=278) vs 3% (n=267) placebo @ 0.43wk30 mg QD
NCT03607422 · Phase 3
56.7% (n=60) vs 3.4% (n=59) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
50% (n=60) vs 3.4% (n=59) placebo @ 4wk30 mg QD
NCT03607422 · Phase 3
5% (n=60) vs 0% (n=59) placebo @ 1wk30 mg QD
NCT03607422 · Phase 3
3.2% (n=62) vs 0% (n=59) placebo @ 0.29wk30 mg QD
NCT03607422 · Phase 3
9.7% (n=62) vs 1.7% (n=59) placebo @ 0.43wk30 mg QD
NCT03607422 · Phase 3
60% (n=280) vs 11.8% (n=272) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
66.8% (n=280) vs 4.4% (n=272) placebo @ 4wk30 mg QD
NCT03569293 · Phase 3
19.6% (n=280) vs 0.4% (n=272) placebo @ 1wk30 mg QD
NCT03569293 · Phase 3
11.8% (n=279) vs 3.7% (n=270) placebo @ 0.29wk30 mg QD
NCT03569293 · Phase 3
21.1% (n=279) vs 3.3% (n=270) placebo @ 0.43wk30 mg QD
NCT03569293 · Phase 3
58.9% (n=56) vs 10.5% (n=57) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
64.3% (n=56) vs 3.5% (n=57) placebo @ 4wk30 mg QD
NCT03569293 · Phase 3
23.2% (n=56) vs 0% (n=57) placebo @ 1wk30 mg QD
NCT03569293 · Phase 3
14% (n=57) vs 1.8% (n=56) placebo @ 0.29wk30 mg QD
NCT03569293 · Phase 3
56.1% (n=334) vs 36.4% (n=323) Dupilumab @ 16wk30 mg QD
NCT03738397 · Phase 3 · registry result, not featured evidence
EASI-90 42.4% (n=276) vs 5.4% (n=278) placebo @ 16wk15 mg QD
responder rate · % of participants
NCT03607422 · Phase 3
show 14 more results
48.3% (n=58) vs 1.7% (n=60) placebo @ 16wk15 mg QD
NCT03607422 · Phase 3
53.1% (n=281) vs 8.1% (n=281) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
47.6% (n=63) vs 3.4% (n=58) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
26.2% (n=42) vs 0% (n=41) placebo @ 8wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
26.2% (n=42) vs 2.4% (n=41) placebo @ 16wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
58.5% (n=282) vs 5.4% (n=278) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
62% (n=62) vs 1.7% (n=60) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
65.8% (n=285) vs 8.1% (n=281) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
74.1% (n=58) vs 3.4% (n=58) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
61.6% (n=342) vs 40.3% (n=331) Dupilumab @ 16wk30 mg QD
NCT03738397 · Phase 3 · registry result, not featured evidence
45.2% (n=42) vs 0% (n=41) placebo @ 8wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
50% (n=42) vs 2.4% (n=41) placebo @ 16wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
9.5% (n=42) vs 0% (n=41) placebo @ 8wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
14.3% (n=42) vs 2.4% (n=41) placebo @ 16wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
Disease Flare 2.2% (n=274) vs 24.5% (n=269) placebo @ 16wk15 mg QD
responder rate · % of participants
NCT03607422 · Phase 3
show 7 more results
1.7% (n=58) vs 20% (n=60) placebo @ 16wk15 mg QD
NCT03607422 · Phase 3
1.1% (n=279) vs 25.2% (n=274) placebo15 mg QD
NCT03569293 · Phase 3
0% (n=62) vs 23.2% (n=56) placebo15 mg QD
NCT03569293 · Phase 3
1.4% (n=277) vs 24.5% (n=269) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
1.6% (n=61) vs 20% (n=60) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
0% (n=285) vs 25.2% (n=274) placebo30 mg QD
NCT03569293 · Phase 3
0% (n=58) vs 23.2% (n=56) placebo30 mg QD
NCT03569293 · Phase 3
EASI 100 14.1% (n=276) vs 0.7% (n=278) placebo @ 16wk15 mg QD
responder rate · % of participants
NCT03607422 · Phase 3
show 8 more results
15.5% (n=58) vs 1.7% (n=60) placebo @ 16wk15 mg QD
NCT03607422 · Phase 3
16.7% (n=281) vs 1.8% (n=281) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
15.9% (n=63) vs 0% (n=58) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
18.8% (n=282) vs 0.7% (n=278) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
19.4% (n=62) vs 1.7% (n=60) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
27% (n=285) vs 1.8% (n=281) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
34.5% (n=58) vs 0% (n=58) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
28.4% (n=342) vs 7.9% (n=331) Dupilumab @ 16wk30 mg QD
NCT03738397 · Phase 3 · registry result, not featured evidence
WI-NRS -51.2% (n=224) vs -17.04% (n=119) placebo @ 16wk15 mg QD
percent change · % of baseline
NCT03607422 · Phase 3
show 7 more results
-47.56% (n=49) vs -11.02% (n=27) placebo @ 16wk15 mg QD
NCT03607422 · Phase 3
-62.79% (n=225) vs -26.06% (n=123) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
-59.01% (n=49) vs -24.36% (n=31) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
-66.49% (n=235) vs -17.04% (n=119) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
-66.95% (n=55) vs -11.02% (n=27) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
-72.04% (n=236) vs -26.06% (n=123) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
-70% (n=51) vs -24.36% (n=31) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
EASI -74.13% (n=246) vs -34.51% (n=142) placebo @ 16wk15 mg QD
percent change · % of baseline
NCT03607422 · Phase 3
show 69 more results
-77.85% (n=53) vs -42.19% (n=31) placebo @ 16wk15 mg QD
NCT03607422 · Phase 3
-80.24% (n=244) vs -40.71% (n=128) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
-82.13% (n=59) vs -43.53% (n=30) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
-61.7% (n=42) vs -23% (n=39) placebo @ 16wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
-65.4% (n=42) vs -17.5% (n=39) placebo @ 8wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
582.3% (n=17) vs 50.7% (n=10) placebo @ 20wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
65.7% (n=18) vs 50.7% (n=10) placebo @ 20wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
607.3% (n=17) vs 13.5% (n=10) placebo @ 24wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
72.6% (n=18) vs 13.5% (n=10) placebo @ 24wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
613.3% (n=17) vs -2.3% (n=10) placebo @ 32wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
151.7% (n=18) vs -2.3% (n=10) placebo @ 32wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
608.8% (n=17) vs -31.2% (n=10) placebo @ 40wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
154.1% (n=18) vs -31.2% (n=10) placebo @ 40wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
613.8% (n=17) vs -29.8% (n=10) placebo @ 52wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
104.1% (n=18) vs -29.8% (n=10) placebo @ 52wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
614.6% (n=17) vs -35.8% (n=10) placebo @ 64wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
104.1% (n=18) vs -35.8% (n=10) placebo @ 64wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
614% (n=17) vs -37.3% (n=10) placebo @ 76wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
130.2% (n=18) vs -37.3% (n=10) placebo @ 76wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
617.5% (n=17) vs -37.7% (n=10) placebo @ 88wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
99.3% (n=18) vs -37.7% (n=10) placebo @ 88wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
-84.65% (n=250) vs -34.51% (n=142) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
-84.81% (n=52) vs -42.19% (n=31) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
-87.74% (n=259) vs -40.71% (n=128) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
-89.42% (n=57) vs -43.53% (n=30) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
-74.4% (n=42) vs -23% (n=39) placebo @ 16wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
-82.8% (n=42) vs -17.5% (n=39) placebo @ 8wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
11.8% (n=10) vs 50.7% (n=10) placebo @ 20wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
791.5% (n=14) vs 50.7% (n=10) placebo @ 20wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
-73.8% (n=19) vs 50.7% (n=10) placebo @ 20wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
-67.5% (n=10) vs 13.5% (n=10) placebo @ 24wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
898.5% (n=14) vs 13.5% (n=10) placebo @ 24wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
-69.6% (n=19) vs 13.5% (n=10) placebo @ 24wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
-83.1% (n=10) vs -2.3% (n=10) placebo @ 32wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
771.5% (n=14) vs -2.3% (n=10) placebo @ 32wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
-28.8% (n=19) vs -2.3% (n=10) placebo @ 32wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
-92% (n=10) vs -31.2% (n=10) placebo @ 40wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
778.9% (n=14) vs -31.2% (n=10) placebo @ 40wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
140.6% (n=19) vs -31.2% (n=10) placebo @ 40wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
-90.1% (n=10) vs -29.8% (n=10) placebo @ 52wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
799.5% (n=14) vs -29.8% (n=10) placebo @ 52wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
-13.3% (n=19) vs -29.8% (n=10) placebo @ 52wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
-91.4% (n=10) vs -35.8% (n=10) placebo @ 64wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
802.1% (n=14) vs -35.8% (n=10) placebo @ 64wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
63.6% (n=19) vs -35.8% (n=10) placebo @ 64wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
-90.3% (n=10) vs -37.3% (n=10) placebo @ 76wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
787.8% (n=14) vs -37.3% (n=10) placebo @ 76wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
24.4% (n=19) vs -37.3% (n=10) placebo @ 76wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
-84.6% (n=10) vs -37.7% (n=10) placebo @ 88wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
769.7% (n=14) vs -37.7% (n=10) placebo @ 88wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
39% (n=19) vs -37.7% (n=10) placebo @ 88wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
-39.4% (n=42) vs -23% (n=39) placebo @ 16wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
-43.7% (n=42) vs -17.5% (n=39) placebo @ 8wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
186% (n=15) vs 50.7% (n=10) placebo @ 20wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
79.1% (n=15) vs 50.7% (n=10) placebo @ 20wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
189.6% (n=15) vs 13.5% (n=10) placebo @ 24wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
59% (n=15) vs 13.5% (n=10) placebo @ 24wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
181.5% (n=15) vs -2.3% (n=10) placebo @ 32wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
63.5% (n=15) vs -2.3% (n=10) placebo @ 32wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
200.9% (n=15) vs -31.2% (n=10) placebo @ 40wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
77.6% (n=15) vs -31.2% (n=10) placebo @ 40wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
189.1% (n=15) vs -29.8% (n=10) placebo @ 52wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
74.4% (n=15) vs -29.8% (n=10) placebo @ 52wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
179.9% (n=15) vs -35.8% (n=10) placebo @ 64wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
71.8% (n=15) vs -35.8% (n=10) placebo @ 64wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
201.4% (n=15) vs -37.3% (n=10) placebo @ 76wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
77.7% (n=15) vs -37.3% (n=10) placebo @ 76wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
170.7% (n=15) vs -37.7% (n=10) placebo @ 88wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
69.1% (n=15) vs -37.7% (n=10) placebo @ 88wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
POEM 4-Point Improvement 70.9% (n=268) vs 28.7% (n=268) placebo @ 16wk15 mg QD
responder rate · % of participants
NCT03607422 · Phase 3
show 7 more results
66.1% (n=56) vs 28.1% (n=57) placebo @ 16wk15 mg QD
NCT03607422 · Phase 3
75% (n=278) vs 22.8% (n=276) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
80.6% (n=62) vs 27.3% (n=55) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
83.5% (n=269) vs 28.7% (n=268) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
80.7% (n=57) vs 28.1% (n=57) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
81.4% (n=280) vs 22.8% (n=276) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
87.9% (n=58) vs 27.3% (n=55) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
DLQI 4-point Improvement 71.7% (n=251) vs 28.4% (n=250) placebo @ 16wk15 mg QD
responder rate · % of participants
NCT03607422 · Phase 3
show 7 more results
68.2% (n=22) vs 19.2% (n=26) placebo @ 16wk15 mg QD
NCT03607422 · Phase 3
75.4% (n=254) vs 29% (n=250) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
81.5% (n=27) vs 33.3% (n=21) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
77.6% (n=251) vs 28.4% (n=250) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
73.3% (n=30) vs 19.2% (n=26) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
82% (n=256) vs 29% (n=250) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
79.3% (n=29) vs 33.3% (n=21) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
SCORAD -57.9% (n=245) vs -28.43% (n=136) placebo @ 16wk15 mg QD
percent change · % of baseline
NCT03607422 · Phase 3
show 13 more results
-57.89% (n=54) vs -27.91% (n=30) placebo @ 16wk15 mg QD
NCT03607422 · Phase 3
-65.71% (n=239) vs -32.68% (n=125) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
-65.42% (n=58) vs -30.9% (n=30) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
-44.1% (n=36) vs -7% (n=33) placebo @ 8wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
-46.9% (n=36) vs -12.4% (n=33) placebo @ 16wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
-68.44% (n=241) vs -28.43% (n=136) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
-72.81% (n=49) vs -27.91% (n=30) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
-73.07% (n=253) vs -32.68% (n=125) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
-76.35% (n=57) vs -30.9% (n=30) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
-65.3% (n=40) vs -7% (n=33) placebo @ 8wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
-60.4% (n=40) vs -12.4% (n=33) placebo @ 16wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
-35.4% (n=39) vs -7% (n=33) placebo @ 8wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
-32.5% (n=39) vs -12.4% (n=33) placebo @ 16wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
DLQI 0/1 23.8% (n=252) vs 4.7% (n=257) placebo @ 16wk15 mg QD
responder rate · % of participants
NCT03607422 · Phase 3
show 7 more results
13.6% (n=22) vs 7.7% (n=26) placebo @ 16wk15 mg QD
NCT03607422 · Phase 3
30.3% (n=258) vs 4.4% (n=252) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
22.2% (n=27) vs 4.8% (n=21) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
37.9% (n=256) vs 4.7% (n=257) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
46.9% (n=32) vs 7.7% (n=26) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
41.5% (n=261) vs 4.4% (n=252) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
30% (n=30) vs 4.8% (n=21) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3

+ 25 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: upadacitinib's landscape · ZL-82's landscape